almagate has been researched along with Macular Holes in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kurihara, T; Nagai, N; Okamoto, T; Ozawa, Y; Shinoda, H; Tsubota, K | 1 |
| Chang, LK; Chiang, A; Sarraf, D; Yu, F | 1 |
| Angulo Bocco, MC; Coscas, G; Glacet-Bernard, A; Soubrane, G; Zourdani, A | 1 |
| Acquah, K; Day, S; Grossman, DS; Lee, PP; Mruthyunjaya, P; Sloan, FA | 1 |
| Bird, A; Dietzel, M; Gutfleisch, M; Heimes, B; Lommatzsch, A; Pauleikhoff, D; Schumacher, M | 1 |
| Bux, AV; Iaculli, C; Noci, ND; Querques, G | 1 |
| Coco, RM; Fernández Muñoz, M; Hernandez, AG; Sanabria, MR | 1 |
| Apte, RS; Blinder, KJ; Dhalla, MS; Hariprasad, SM; Tewari, A | 1 |
| Sears, JE; Singh, RP | 1 |
| Chang, LK; Flaxel, CJ; Lauer, AK; Sarraf, D | 1 |
1 trial(s) available for almagate and Macular Holes
| Article | Year |
|---|---|
Retinal pigment epithelium tears in age-related macular degeneration treated with antiangiogenic drugs: a controlled study with long follow-up.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Case-Control Studies; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Ranibizumab; Retinal Perforations; Retinal Pigment Epithelium; Retrospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity | 2012 |
9 other study(ies) available for almagate and Macular Holes
| Article | Year |
|---|---|
Intraoperative and fluorescein angiographic findings of a secondary macular hole associated with age-related macular degeneration treated by pars plana vitrectomy.
Topics: Aged; Aptamers, Nucleotide; Basement Membrane; Coloring Agents; Epiretinal Membrane; Fluorescein Angiography; Humans; Indocyanine Green; Intraoperative Period; Male; Retinal Perforations; Vascular Endothelial Growth Factor A; Vitrectomy; Wet Macular Degeneration | 2014 |
Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Macular Degeneration; Male; Predictive Value of Tests; Ranibizumab; Retinal Detachment; Retinal Perforations; Retinal Pigment Epithelium; Retinal Vessels; Retrospective Studies; Risk Assessment; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A | 2008 |
[Intravitreous injection: retrospective study on 2028 injections and their side effects].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Cataract; Diabetic Retinopathy; Endophthalmitis; Epiretinal Membrane; Humans; Injections; Macular Degeneration; Macular Edema; Ocular Hypertension; Ranibizumab; Retinal Detachment; Retinal Perforations; Retinal Vein Occlusion; Retrospective Studies; Risk Assessment; Triamcinolone Acetonide; Vitreous Body; Vitreous Hemorrhage | 2008 |
Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Case-Control Studies; Endophthalmitis; Eye Diseases; Female; Follow-Up Studies; Health Services Research; Humans; Incidence; Intravitreal Injections; Macular Degeneration; Male; Medicare Part B; Proportional Hazards Models; Ranibizumab; Retinal Detachment; Retinal Perforations; Retrospective Studies; United States; Uveitis; Vascular Endothelial Growth Factor A; Vitreous Hemorrhage | 2011 |
Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Female; Fluorescein Angiography; Humans; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Pigment Epithelium of Eye; Ranibizumab; Retinal Detachment; Retinal Perforations; Tomography, Optical Coherence; Vascular Endothelial Growth Factors; Visual Acuity | 2011 |
Lamellar macular hole following intravitreal pegaptanib sodium (Macugen) injection for diabetic macular edema.
Topics: Aged; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Humans; Intravitreal Injections; Macular Edema; Retinal Perforations; Vascular Endothelial Growth Factor A | 2011 |
Retinal pigment epithelial tear following intravitreal pegaptanib sodium.
Topics: Aged; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Indocyanine Green; Injections; Macular Degeneration; Male; Pigment Epithelium of Eye; Retinal Detachment; Retinal Perforations; Tomography, Optical Coherence; Visual Acuity | 2006 |
Retinal pigment epithelial tears after pegaptanib injection for exudative age-related macular degeneration.
Topics: Aged; Aptamers, Nucleotide; Exudates and Transudates; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration; Pigment Epithelium of Eye; Retinal Perforations; Rupture | 2006 |
RPE tears after pegaptanib treatment in age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration; Male; Pigment Epithelium of Eye; Postoperative Complications; Retinal Perforations; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2007 |